PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 1, 1998Clinical Cardiology50 citationsOpen Access

Comparison of epirubicin and doxorubicin cardiotoxicity induced by low doses: Evolution of the diastolic and systolic parameters studied by radionucide angiography

View Full Paper
YCYves CottinPLPierre LouisJWJean Eric Wolf

Structured PICO

Does low-dose epirubicin compared to doxorubicin reduce cardiotoxicity in patients undergoing chemotherapy?

P
Population
99 patients without cardiac disease undergoing chemotherapy, mean age 51 +/- 12 years.
I
Intervention
Epirubicin (EPI) at an equivalent dose of 219 +/- 92 mg/m2 of doxorubicin
C
Comparator
Doxorubicin (DXR) 246 +/- 96 mg/m2
O
Outcome
Cardiotoxicity measured by left ventricular ejection fraction (EF), peak ejection rate (PER), and peak filling rate (PFR) via gated radionuclide angiography at 1 month after the end of chemotherapysurrogate

Low-dose epirubicin preserves diastolic function (peak filling rate) better than equivalent doses of doxorubicin, despite similar moderate declines in systolic function.

Abstract

BACKGROUND: Previous studies have demonstrated that epirubicin (EPI) has a lower propensity to produce cardiotoxic effects than doxorubicin (DXR) at high doses. HYPOTHESIS: The aim of the study was to compare the cardiotoxicity induced by low doses of EPI and DXR in patients before and 1 month after the end of chemotherapy. METHOD: In a prospective study, 99 patients with a mean age of 51 +/- 12 years and without cardiac disease were studied before and 1 month after the end of chemotherapy. Group 1 included 38 patients receiving 246 +/- 96 mg/m2 of DXR and Group 2 included 61 patients receiving EPI with and equivalent dose of 219 +/- 92 mg/m2 of DXR. Ejection fraction (EF) of the left ventricle (LV), peak ejection rate (PER), and peak filling rate (PFR) expressed in end-diastolic volume/s (EDV/s) were evaluated by gated radionuclide angiography; PFR/PER were also calculated. RESULTS: Moderate and similar alterations of left ventricular ejection fraction were shown for low doses of anthracyclines. The EF of the LV decreased from 57 +/- 6% to 54 +/- 6% for DXR group (Group 1) (p = 0.005), and from 58 +/- 5% to 55 +/- 5% for the EPI group (Group 2)(p = 0.001). The PER of the left ventricle fell from 3.08 +/- 0.46 EDV/s to 2.79 +/- 0.49 in Group 1 (p = 0.004) and from 2.98 +/- 0.50 to 2.73 +/- 0.34 EDV/s in Group 2 (p = 0.001). In contrast, no significant alteration of PFR appeared in Group 2 (from 2.72 +/- 0.51 to 2.62 +/- 0.41 EDV/s) for the equivalent dose of anthracycline, while PFR of the LV dropped from 2.82 +/- 0.76 (EDV/s) to 2.41 +/- 0.55 after doxorubicin (p = 0.004). No difference was found between 1 and 12 months after the end of the treatment in 25 patients in Group 1 and 28 patients in Group 2. These results confirm the advantage of EPI over DXR in terms of cardiotoxicity and help explain the relationship of cellular damage mechanisms with the functional parameters of nuclear investigation. CONCLUSION: A possible explanation for specific alteration after DXR could be the increased production of semiquinone free radicals, which are known to induce membrane damage and, consequently, myocardial edema and diastolic alteration.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Cottin et al. (1998) studied this question.

synapsesocial.com/papers/6a712bff78a11c550e0b39d0https://doi.org/10.1002/clc.4960210911
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cardiotoxicity of epirubicin and doxorubicin: A double‐blind randomized study1991 · 72 citations
  2. 2A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.1985 · 251 citations
  3. 3Pharmacological interventions for preventing anthracycline-induced clinical and subclinical cardiotoxicity: A network meta-analysis of metastatic breast cancer2020 · 16 citations
  4. 4Subclinical cardiotoxicity by doxorubicin: a pulsed Doppler echocardiographic study<xref ref-type="fn" rid="fn1" />1991 · 24 citations
  5. 5A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer.1991 · 117 citations